AI Insight
A new film titled "You Can See Everything" has renewed public attention on blood-testing startups, examining how the industry continues to operate in the aftermath of the Theranos scandal involving Elizabeth Holmes. The article discusses how Holmes's fraudulent claims about revolutionary blood-testing technology and subsequent conviction continue to cast a shadow over legitimate companies working in the diagnostic testing space. The piece explores the ongoing tension between innovation in medical diagnostics and the lasting reputational damage caused by the Theranos case.
Why it matters
The Theranos scandal has created increased scrutiny and skepticism toward blood-testing startups, potentially affecting funding and public trust in legitimate diagnostic innovations. Understanding how the industry navigates this legacy is important for maintaining progress in medical testing while ensuring proper oversight and preventing future fraud.
Understand the Science
Nature, Published online: 23 October 2026; doi:10.1038/d41586-026-03383-7
You Can See Everything brings blood-testing start-ups back into the public eye. They persevere in Theranos’s shadow.
Source: Elizabeth Holmes film enthralls — but her legacy haunts science